Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
5.61
+0.18 (3.31%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Insight Molecular Diagnostics Employees
As of December 31, 2025, Insight Molecular Diagnostics had 58 total employees, including 55 full-time and 3 part-time employees. The number of employees increased by 9 or 18.37% compared to the previous year.
Employees
58
Change (1Y)
9
Growth (1Y)
18.37%
Revenue / Employee
$33,603
Profits / Employee
-$824,845
Market Cap
181.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 58 | 9 | 18.37% | 55 | 3 |
| Dec 31, 2024 | 49 | 3 | 6.52% | 46 | 3 |
| Dec 31, 2023 | 46 | -30 | -39.47% | 43 | 3 |
| Dec 31, 2022 | 76 | -39 | -33.91% | 75 | 1 |
| Dec 31, 2021 | 115 | 64 | 125.49% | 110 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 942 |
| Burning Rock Biotech | 667 |
| MDxHealth | 364 |
| Biodesix | 334 |
| Personalis | 260 |
IMDX News
- 1 day ago - IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - GlobeNewsWire
- 3 days ago - iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - GlobeNewsWire
- 4 weeks ago - Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Insight Molecular Diagnostics Earnings release: Q1 2026 - Filings
- 4 weeks ago - Insight Molecular Diagnostics Shareholder letter: Q1 2026 - Filings
- 4 weeks ago - Insight Molecular Diagnostics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - GlobeNewsWire
- 4 weeks ago - Insight Molecular Diagnostics Slides: Investor presentation - Filings